• metastatic/advanced OC (mOC) - 1st line (L1)
• mOC - L1 - all population 1
• mOC - L1 - PDL1 positive 1

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus SoC

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs placebo plus SoC

  All patients Age > 65y Asian type ECOG 0 ECOG 1 PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) stage III (locally advanced) stage IV (metastatic)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

metastatic/advanced OC (mOC) - 1st line (L1), atezolizumab based treatment vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;